CA2970864C - Solid state forms of fused heteroaromatic pyrrolidinones - Google Patents

Solid state forms of fused heteroaromatic pyrrolidinones Download PDF

Info

Publication number
CA2970864C
CA2970864C CA2970864A CA2970864A CA2970864C CA 2970864 C CA2970864 C CA 2970864C CA 2970864 A CA2970864 A CA 2970864A CA 2970864 A CA2970864 A CA 2970864A CA 2970864 C CA2970864 C CA 2970864C
Authority
CA
Canada
Prior art keywords
compound
cancer
certain embodiments
shows
chemical entity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2970864A
Other languages
English (en)
French (fr)
Other versions
CA2970864A1 (en
Inventor
Rongliang Chen
Tomonori ICHIBAKASE
Chunrong Ma
Christopher Matthews
Hajime MOTOYOSHI
Colin O'Bryan
Kentaro YAJI
Naoki Yoshikawa
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2970864(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA2970864A1 publication Critical patent/CA2970864A1/en
Application granted granted Critical
Publication of CA2970864C publication Critical patent/CA2970864C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CA2970864A 2014-12-18 2015-12-17 Solid state forms of fused heteroaromatic pyrrolidinones Active CA2970864C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462093564P 2014-12-18 2014-12-18
US62/093,564 2014-12-18
US201562115223P 2015-02-12 2015-02-12
US62/115,223 2015-02-12
US201562180222P 2015-06-16 2015-06-16
US62/180,222 2015-06-16
PCT/IB2015/002489 WO2016097862A2 (en) 2014-12-18 2015-12-17 Solid state forms of fused heteroaromatic pyrrolidinones

Publications (2)

Publication Number Publication Date
CA2970864A1 CA2970864A1 (en) 2016-06-23
CA2970864C true CA2970864C (en) 2020-04-14

Family

ID=55299676

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2970864A Active CA2970864C (en) 2014-12-18 2015-12-17 Solid state forms of fused heteroaromatic pyrrolidinones

Country Status (29)

Country Link
US (3) US10676473B2 (enExample)
EP (2) EP3677582B1 (enExample)
JP (3) JP6778195B2 (enExample)
KR (1) KR102037502B1 (enExample)
CN (1) CN107108609B (enExample)
AU (1) AU2015365580B2 (enExample)
BR (1) BR112017013149B1 (enExample)
CA (1) CA2970864C (enExample)
CL (1) CL2017001561A1 (enExample)
CO (1) CO2017005910A2 (enExample)
CR (1) CR20170249A (enExample)
DK (1) DK3233857T3 (enExample)
DO (1) DOP2017000130A (enExample)
EA (1) EA032291B1 (enExample)
EC (1) ECSP17038100A (enExample)
ES (1) ES2788454T3 (enExample)
GE (2) GEP20197050B (enExample)
IL (1) IL252941B (enExample)
MX (1) MX373586B (enExample)
MY (1) MY199935A (enExample)
NZ (1) NZ732371A (enExample)
PE (1) PE20171179A1 (enExample)
PH (1) PH12017501123A1 (enExample)
PL (1) PL3233857T3 (enExample)
SG (1) SG11201701911QA (enExample)
TN (1) TN2017000080A1 (enExample)
UA (1) UA120632C2 (enExample)
WO (1) WO2016097862A2 (enExample)
ZA (1) ZA201701800B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000080A1 (en) * 2014-12-18 2018-07-04 Takeda Pharmaceuticals Co Solid state forms of fused heteroaromatic pyrrolidinones
US20190231757A1 (en) * 2016-07-13 2019-08-01 Takeda Pharmaceutical Company Limited Combination of spleen tyrosine kinase inhibitors and other therapeutic agents
CN111194319A (zh) 2017-10-19 2020-05-22 拜耳动物保健有限责任公司 稠合的杂芳族吡咯烷酮类化合物用于治疗和预防动物中的疾病的用途
WO2019088039A1 (en) 2017-10-30 2019-05-09 Takeda Pharmaceutical Company Limited Treatment of acute myeloid leukemia
WO2020119785A1 (zh) * 2018-12-14 2020-06-18 正大天晴药业集团股份有限公司 一种Syk抑制剂的盐及其结晶型
BR112021014456A2 (pt) 2019-02-07 2021-09-21 Janssen Biotech, Inc. Inibidores de di-hidro-orotato desidrogenase
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
JP2022552496A (ja) 2019-10-10 2022-12-16 ヤンセン バイオテツク，インコーポレーテツド ビアリールジヒドロオロト酸デヒドロゲナーゼ阻害剤
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
WO2022074534A1 (en) 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents
WO2022127753A1 (zh) * 2020-12-18 2022-06-23 山东轩竹医药科技有限公司 稠环类AhR抑制剂
PE20240588A1 (es) 2021-05-11 2024-03-21 Janssen Pharmaceutica Nv Terapias de combinacion
MX2023013410A (es) 2021-05-11 2023-12-06 Janssen Pharmaceutica Nv Terapias de combinacion.
KR102539612B1 (ko) 2021-12-24 2023-06-02 엘에스일렉트릭(주) IP 기반 RAPIEnet을 지원하는 통신 디바이스 및 이를 포함하는 네트워크 시스템
WO2024114666A1 (en) 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
EP4626426A1 (en) 2022-11-30 2025-10-08 JANSSEN Pharmaceutica NV Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070872A1 (en) * 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
NZ601267A (en) 2009-12-23 2014-03-28 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
WO2016048982A2 (en) * 2014-09-24 2016-03-31 Millennium Pharmaceuticals, Inc. COMBINATION TREATMENT WITH PI3Kα INHIBITORS AND TAXANES
TN2017000080A1 (en) * 2014-12-18 2018-07-04 Takeda Pharmaceuticals Co Solid state forms of fused heteroaromatic pyrrolidinones

Also Published As

Publication number Publication date
EP3677582B1 (en) 2023-01-25
SG11201701911QA (en) 2017-04-27
US20230348461A1 (en) 2023-11-02
PE20171179A1 (es) 2017-08-22
CN107108609A (zh) 2017-08-29
MY199935A (en) 2023-11-29
BR112017013149A2 (pt) 2018-04-10
HK1243406A1 (zh) 2018-07-13
JP6778195B2 (ja) 2020-10-28
GEP20197050B (en) 2019-12-10
GEAP201914545A (en) 2019-08-12
JP2017537969A (ja) 2017-12-21
US20200339573A1 (en) 2020-10-29
ES2788454T3 (es) 2020-10-21
IL252941B (en) 2020-11-30
PL3233857T3 (pl) 2020-07-27
JP2020143081A (ja) 2020-09-10
CA2970864A1 (en) 2016-06-23
KR20170095374A (ko) 2017-08-22
TN2017000080A1 (en) 2018-07-04
EP3233857B1 (en) 2020-03-11
JP2022017477A (ja) 2022-01-25
CR20170249A (es) 2017-09-25
DOP2017000130A (es) 2017-07-15
US20160176869A1 (en) 2016-06-23
IL252941A0 (en) 2017-08-31
EA201791369A1 (ru) 2017-10-31
ZA201701800B (en) 2020-05-27
MX2017007162A (es) 2017-08-28
JP6974534B2 (ja) 2021-12-01
EA032291B1 (ru) 2019-05-31
AU2015365580B2 (en) 2020-04-02
CL2017001561A1 (es) 2018-01-12
DK3233857T3 (da) 2020-04-27
NZ732371A (en) 2023-04-28
US11352355B2 (en) 2022-06-07
EP3677582A1 (en) 2020-07-08
WO2016097862A3 (en) 2016-08-11
ECSP17038100A (es) 2017-12-01
AU2015365580A1 (en) 2017-07-06
US10676473B2 (en) 2020-06-09
BR112017013149B1 (pt) 2022-10-11
PH12017501123A1 (en) 2017-11-27
KR102037502B1 (ko) 2019-10-28
WO2016097862A2 (en) 2016-06-23
CO2017005910A2 (es) 2017-10-20
EP3233857A2 (en) 2017-10-25
CN107108609B (zh) 2020-02-18
UA120632C2 (uk) 2020-01-10
MX373586B (es) 2020-05-05

Similar Documents

Publication Publication Date Title
CA2970864C (en) Solid state forms of fused heteroaromatic pyrrolidinones
TWI457339B (zh) 稠合雜芳香環吡咯啶酮
AU2020211000B2 (en) Stable solid dispersions of B-RAF kinase dimer inhibitor, methods of preparation, and uses therefor
IL267532A (en) Preparations and methods for inhibiting arginase activity
PH12015501192B1 (en) Boronate ester compounds and pharmaceutical compositions thereof
CA2995909A1 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
HK40033008B (en) Solid state forms of fused heteroaromatic pyrrolidinones
JP2019532021A (ja) Ｃ５ａ受容体アンタゴニストとしての環状ペプチド
HK40033008A (en) Solid state forms of fused heteroaromatic pyrrolidinones
ES2900048T3 (es) Nueva sal de N-(2,6-dietilfenil)-8-({4-[4-(dimetilamino)piperidin-1-il]-2-metoxifenil}amino)-1-metil-4,5-dihidro-1H-pirazolo[4,3-h]quinazolin-3-carboxamida, su preparación y formulaciones que la contienen
JP2024514532A (ja) 大環状アゾロピリジン
TWI652266B (zh) 經取代咪唑並吡啶基胺基吡啶化合物之鹽類和多晶型
HK1243406B (zh) 稠合杂芳族吡咯烷酮的固态形式
EA052614B1 (ru) Стабильные твердые дисперсии ингибитора димера киназы b-raf, способы их получения и их применения
EA047214B1 (ru) СТАБИЛЬНЫЕ ТВЕРДЫЕ ДИСПЕРСИИ ИНГИБИТОРА ДИМЕРА КИНАЗЫ B-Raf, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЯ
HK40022862B (en) Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it
HK40022862A (en) Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170804

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250929

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226